Dr Reddy's Market Outlook Forecasts and Analysis to 2012

Founded by Indian Scientist Dr Anji Reddy in 1984, the company has developed into a fast-growing international corporation, with headquarters in Hyderabad, Andhra Pradesh, India. During the fiscal year 2006, Dr. Reddy’s was the third-largest Indian pharmaceutical company, with net revenue of $546m. However they have not rested there. Throughout 2007, Dr. Reddy’s has been jostling for leadership among the Indian companies, due to spectacular growth in recent quarters. This company is moving rapidly. Are they a major competitor of yours? Are you partnering with them? Whatever your relationship with the company you need to be fully aware of how they operate and will develop over the next 5 years.

Dr. Reddy’s products are marketed to over 100 countries, including the US, Europe, Russia, Asia Pacific, India and China. While the company’s main strength has so far been generic drugs, Dr. Reddy’s conducts drug discovery and development with the aim of being a discovery-led company with at least one NCE on the market by 2010. It has an ambitious corporate strategy that is also active in acquisitions, international expansion and strategic partnerships, including authorised generics.

Dr. Reddy’s Market Outlook 2012 examines that company critically, through comprehensive research and analysis. Importantly, visiongain discusses Dr. Reddy’s Laboratories in the context of the wider pharmaceutical market. This market-based research involved a detailed study of commercial documents, databases, company reports and relevant news. Importantly, visiongain applied techniques such as financial forecasting, SWOT analysis and qualitative projections. With agreements already in place with Big Pharma, how will these develop when Dr Reddy begins to launch their own original drug formulations - find out today.

In particular, Dr. Reddy’s Laboratories 2007-2012 concentrates on the following essential aspects of that company:

Detailed analysis of Dr. Reddy’s divisions and the performance of its products

Sales forecasts for all the Dr. Reddy’s divisions and the overall group

Discussions of issues affecting the relevant market segments, including competitor analysis

Drivers and opportunities for Dr. Reddy’s

Restraints and threats facing the company

Discussions of company strategy in the context of the market

Strategic alliances and licensing

International operations

Pipeline developments and their implications for the future

A discussion of Dr. Reddy’s domestic Indian market, especially its characteristics and competitive landscape

Leading Indian companies such as Dr. Reddy’s have established a new paradigm for drug development in India, one of the leading developing economies and markets for pharmaceuticals. Visiongain predicts that Dr. Reddy’s revenues and market share will continue to rise strongly, as it harnesses opportunities in the expanding generics market and makes further progress on its quest to be an global discovery led company.

Methodology

The information contained in this report is from primary industry sources. This includes one-on-one interviews with companies, with governmental bodies and academic insitutions. Analysis has also been drawn from company reports, whether annual financial returns or white papers. The author of this report has dealt with over 50+ companies and industry contacts to assist on the production of this report.

Targeted directly at you this report is designed to be used primarily by executives, investors, venture capitalists, and business development managers and analysts involved in the pharmaceutical or biotechnology areas that may have an interest in how Dr. Reddys is set to develop and expand.

Unique benefits to you when you order this report:

- Immediate access through our exclusive Reading Room

- You can access your report whichever country you are in without using harddrive space

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Full searchable report when you buy the company or corporate editions

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

Publication Date: 11/04/07

Pages: 153

PDF Format
Table of Contents

Price
Single User Licence $2998.00
Department Licence 5 Users $5998.00
Company-wide Intranet Licence $9998.00